{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:35:25Z","timestamp":1791207325334,"version":"4.1.0"},"reference-count":180,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["17107"],"award-info":[{"award-number":["17107"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009097","name":"Fondazione Cariparma","doi-asserted-by":"publisher","award":["3576\/2017"],"award-info":[{"award-number":["3576\/2017"]}],"id":[{"id":"10.13039\/100009097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009097","name":"Fondazione Cariparma","doi-asserted-by":"publisher","award":["0180\/2018"],"award-info":[{"award-number":["0180\/2018"]}],"id":[{"id":"10.13039\/100009097","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondazione Grande Ale Onlus","award":["01-2018"],"award-info":[{"award-number":["01-2018"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chemoresistance is a major cause of recurrence and death from T-cell acute lymphoblastic leukemia (T-ALL), both in adult and pediatric patients. In the majority of cases, drug-resistant disease is treated by selecting a combination of other drugs, without understanding the molecular mechanisms by which malignant cells escape chemotherapeutic treatments, even though a more detailed genomic characterization and the identification of actionable disease targets may enable informed decision of new agents to improve patient outcomes. In this work, we describe pathways of resistance to common chemotherapeutic agents including glucocorticoids and review the resistance mechanisms to targeted therapy such as IL7R, PI3K-AKT-mTOR, NOTCH1, BRD4\/MYC, Cyclin D3: CDK4\/CDK6, BCL2 inhibitors, and selective inhibitors of nuclear export (SINE). Finally, to overcome the limitations of the current trial-and-error method, we summarize the experiences of anti-cancer drug sensitivity resistance profiling (DSRP) approaches as a rapid and relevant strategy to infer drug activity and provide functional information to assist clinical decision one patient at a time.<\/jats:p>","DOI":"10.3390\/ijms20123021","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T10:49:59Z","timestamp":1561027799000},"page":"3021","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.3390","volume":"20","author":[{"given":"Elena","family":"Follini","sequence":"first","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9489-7899","authenticated-orcid":false,"given":"Matteo","family":"Marchesini","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Roti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"key":"ref_1","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., and Vardiman, J.W. (2016). WHO Classification of Tumours, IARC. [Revised 4th ed.]. WHO classification of tumours of haematopoietic and lymphoid tissues."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.6004\/jnccn.2017.0147","article-title":"Nccn guidelines insights: Acute lymphoblastic leukemia, version 1.2017","volume":"15","author":"Brown","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_3","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European group for the immunological characterization of leukemias (egil)","volume":"9","author":"Bene","year":"1995","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2016-07-692608","article-title":"Management of adults with T-cell lymphoblastic leukemia","volume":"129","author":"Marks","year":"2017","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Mullighan","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.blre.2017.08.006","article-title":"T cell acute lymphoblastic leukemia (t-all): New insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies","volume":"32","author":"Vadillo","year":"2018","journal-title":"Blood Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","article-title":"Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: A group for research on adult acute lymphoblastic leukemia study","volume":"35","author":"Bond","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.86.6.2031","article-title":"Chromosomal translocation in a human leukemic stem-cell line disrupts the t-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript","volume":"86","author":"Begley","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11416","DOI":"10.1073\/pnas.88.24.11416","article-title":"Tal2, a helix-loop-helix gene activated by the (7;9)(q34;q32) translocation in human t-cell leukemia","volume":"88","author":"Xia","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2015.38","article-title":"Genomics in acute lymphoblastic leukaemia: Insights and treatment implications","volume":"12","author":"Roberts","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","article-title":"Genetic basis of acute lymphoblastic leukemia","volume":"35","author":"Iacobucci","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","article-title":"The genetics and molecular biology of t-all","volume":"129","author":"Girardi","year":"2017","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early t-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3324\/haematol.2015.129692","article-title":"Pediatric t-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation","volume":"100","author":"Kunz","year":"2015","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.1038\/ncomms7604","article-title":"Rise and fall of subclones from diagnosis to relapse in pediatric b-acute lymphoblastic leukaemia","volume":"6","author":"Ma","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nm.3078","article-title":"Activating mutations in the nt5c2 nucleotidase gene drive chemotherapy resistance in relapsed all","volume":"19","author":"Tzoneva","year":"2013","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1084\/jem.20180570","article-title":"Prc2 loss induces chemoresistance by repressing apoptosis in t cell acute lymphoblastic leukemia","volume":"215","author":"Aries","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_18","first-page":"374","article-title":"Treatment of acute lymphoblastic leukemia in children and adolescents: Peaks and pitfalls","volume":"2008","author":"Seibel","year":"2008","journal-title":"ASH Educ. Program Book"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1200\/JCO.2003.08.047","article-title":"Cns-directed therapy for childhood acute lymphoblastic leukemia: Childhood all collaborative group overview of 43 randomized trials","volume":"21","author":"Clarke","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-cvad), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/MPH.0b013e31822d4d4e","article-title":"Polyethylene glycol-conjugated l-asparaginase versus native l-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: A children\u2019s oncology group study (pog 8866)","volume":"33","author":"Kurtzberg","year":"2011","journal-title":"J. Pediatric Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood-2007-02-070342","article-title":"Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the children\u2019s oncology group","volume":"111","author":"Seibel","year":"2008","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.V93.9.2817","article-title":"Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia","volume":"93","author":"Relling","year":"1999","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory t-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and leukemia group b study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1182\/blood-2011-01-329441","article-title":"High single-drug activity of nelarabine in relapsed t-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation","volume":"118","author":"Gokbuget","year":"2011","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase ii study of nelarabine (compound 506u78) in children and young adults with refractory t-cell malignancies: A report from the children\u2019s oncology group","volume":"23","author":"Berg","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2005.03.199","article-title":"Phase i study of 506u78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies","volume":"23","author":"Kurtzberg","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1038\/leu.2017.136","article-title":"Jak\/stat pathway inhibition overcomes il7-induced glucocorticoid resistance in a subset of human t-cell acute lymphoblastic leukemias","volume":"31","author":"Meyer","year":"2017","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Li, Y., Buijs-Gladdines, J.G., Cante-Barrett, K., Stubbs, A.P., Vroegindeweij, E.M., Smits, W.K., van Marion, R., Dinjens, W.N., Horstmann, M., and Kuiper, R.P. (2016). Il-7 receptor mutations and steroid resistance in pediatric t cell acute lymphoblastic leukemia: A genome sequencing study. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002200"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13105","DOI":"10.18632\/oncotarget.3524","article-title":"Pi3k inhibition synergizes with glucocorticoids but antagonizes with methotrexate in t-cell acute lymphoblastic leukemia","volume":"6","author":"Silveira","year":"2015","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.ccr.2013.10.022","article-title":"Direct reversal of glucocorticoid resistance by akt inhibition in acute lymphoblastic leukemia","volume":"24","author":"Piovan","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8097","DOI":"10.1158\/0008-5472.CAN-10-1814","article-title":"Activity of the novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor nvp-bez235 against t-cell acute lymphoblastic leukemia","volume":"70","author":"Chiarini","year":"2010","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/1078-0432.CCR-15-0114","article-title":"Modulation of glucocorticoid resistance in pediatric t-cell acute lymphoblastic leukemia by increasing bim expression with the pi3k\/mtor inhibitor bez235","volume":"22","author":"Hall","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_34","first-page":"463","article-title":"The dual kinase inhibitor nvp-bez235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells","volume":"32","author":"Schult","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/leu.2013.369","article-title":"Activity of the pan-class i phosphoinositide 3-kinase inhibitor nvp-bkm120 in t-cell acute lymphoblastic leukemia","volume":"28","author":"Lonetti","year":"2014","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ajh.24568","article-title":"Buparlisib, a pi3k inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase i trial of patients with advanced leukemias","volume":"92","author":"Ragon","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor","volume":"16","author":"Janes","year":"2010","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/1078-0432.CCR-18-0867","article-title":"Notch1 represses mcl-1 levels in gsi-resistant t-all, making them susceptible to abt-263","volume":"25","author":"Dastur","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3324\/haematol.11894","article-title":"In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of t-cell acute lymphoblastic leukemia","volume":"93","author":"Lahortiga","year":"2008","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"a000539","DOI":"10.1101\/mcs.a000539","article-title":"Complete hematologic response of early t-cell progenitor acute lymphoblastic leukemia to the gamma-secretase inhibitor bms-906024: Genetic and epigenetic findings in an outlier case","volume":"1","author":"Knoechel","year":"2015","journal-title":"Mol. Case Stud."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ccr.2013.01.015","article-title":"Complementary genomic screens identify serca as a therapeutic target in notch1 mutated cancer","volume":"23","author":"Roti","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1084\/jem.20151778","article-title":"Leukemia-specific delivery of mutant notch1 targeted therapy","volume":"215","author":"Roti","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1182\/blood-2013-08-522698","article-title":"C-myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric t-all cells","volume":"123","author":"Roderick","year":"2014","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.18632\/oncotarget.1873","article-title":"Therapeutic targeting of c-myc in t-cell acute lymphoblastic leukemia, t-all","volume":"5","author":"Loosveld","year":"2014","journal-title":"Oncotarget"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ccr.2012.09.015","article-title":"The requirement for cyclin d function in tumor maintenance","volume":"22","author":"Choi","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccr.2012.09.016","article-title":"Therapeutic targeting of the cyclin d3:Cdk4\/6 complex in t cell leukemia","volume":"22","author":"Sawai","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-15-2869","article-title":"Synergistic drug combinations with a cdk4\/6 inhibitor in t-cell acute lymphoblastic leukemia","volume":"23","author":"Pikman","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","article-title":"Bh3 inhibitor sensitivity and bcl-2 dependence in primary acute lymphoblastic leukemia cells","volume":"75","author":"Alford","year":"2015","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"Abt-199 mediated inhibition of bcl-2 as a novel therapeutic strategy in t-cell acute lymphoblastic leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of t-cell acute lymphoblastic leukemia determines bcl-2 versus bcl-xl dependence and sensitivity to abt-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1158\/1078-0432.CCR-14-0259","article-title":"Cell and molecular determinants of in vivo efficacy of the bh3 mimetic abt-263 against pediatric acute lymphoblastic leukemia xenografts","volume":"20","author":"Suryani","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/leu.2013.377","article-title":"Bcl2-specific inhibitor abt-199 synergizes strongly with cytarabine against the early immature loucy cell line but not more-differentiated t-all cell lines","volume":"28","author":"Anderson","year":"2014","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41375-018-0201-2","article-title":"The mcl1-specific inhibitor s63845 acts synergistically with venetoclax\/abt-199 to induce apoptosis in t-cell acute lymphoblastic leukemia cells","volume":"33","author":"Li","year":"2019","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/leu.2013.366","article-title":"Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of notch1 in t-cell acute lymphoblastic leukemia","volume":"28","author":"Koyama","year":"2014","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","article-title":"Strategic therapeutic targeting to overcome venetoclax resistance in aggressive b-cell lymphomas","volume":"24","author":"Pham","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"22605","DOI":"10.18632\/oncotarget.25194","article-title":"Inhibiting janus kinase 1 and bcl-2 to treat t cell acute lymphoblastic leukemia with il7-ralpha mutations","volume":"9","author":"Senkevitch","year":"2018","journal-title":"Oncotarget"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bcp.2011.12.016","article-title":"Nuclear export of proteins and drug resistance in cancer","volume":"83","author":"Turner","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.semcancer.2014.03.001","article-title":"Inhibition of crm1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents","volume":"27","author":"Turner","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjh.12231","article-title":"Kpt-330 inhibitor of crm1 (xpo1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of t-cell acute lymphoblastic leukaemia and acute myeloid leukaemia","volume":"161","author":"Etchin","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.01.003","article-title":"The 5\u2032-nucleotidases as regulators of nucleotide and drug metabolism","volume":"107","author":"Hunsucker","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cccn.2005.05.006","article-title":"Role of 5\u2032-nucleotidase in thiopurine metabolism: Enzyme kinetic profile and association with thio-gmp levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment","volume":"361","author":"Brouwer","year":"2005","journal-title":"Clin. Chim. Acta"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nature25186","article-title":"Clonal evolution mechanisms in nt5c2 mutant-relapsed acute lymphoblastic leukaemia","volume":"553","author":"Tzoneva","year":"2018","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ccell.2018.06.003","article-title":"Structure and mechanisms of nt5c2 mutations driving thiopurine resistance in relapsed lymphoblastic leukemia","volume":"34","author":"Dieck","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood-2019-01-852392","article-title":"Genetics and mechanisms of nt5c2-driven chemotherapy resistance in relapsed all","volume":"133","author":"Dieck","year":"2019","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz","year":"2017","journal-title":"Oncotarget"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.canlet.2013.11.002","article-title":"Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer","volume":"344","author":"Rihani","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1158\/0008-5472.CAN-08-1856","article-title":"Reversal of p-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3","volume":"69","author":"Michaelis","year":"2009","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0959-437X(96)80091-8","article-title":"P-glycoprotein and multidrug resistance","volume":"6","author":"Gottesman","year":"1996","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4161\/cc.3.4.801","article-title":"Small-molecule antagonists of p53-mdm2 binding: Research tools and potential therapeutics","volume":"3","author":"Vassilev","year":"2004","journal-title":"Cell Cycle"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1182\/blood-2005-02-0553","article-title":"Mdm2 antagonists induce p53-dependent apoptosis in aml: Implications for leukemia therapy","volume":"106","author":"Kojima","year":"2005","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.V85.6.1608.bloodjournal8561608","article-title":"Overexpression of the mdm2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene","volume":"85","author":"Zhou","year":"1995","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.leu.2401619","article-title":"Incidence and prognostic significance of mdm2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia","volume":"14","author":"Zhou","year":"2000","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/leu.2008.11","article-title":"Mdm2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of mdm2","volume":"22","author":"Gu","year":"2008","journal-title":"Leukemia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","article-title":"Gene expression signatures define novel oncogenic pathways in t cell acute lymphoblastic leukemia","volume":"1","author":"Ferrando","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-14-2300","article-title":"Effective targeting of the p53-mdm2 axis in preclinical models of infant mll-rearranged acute lymphoblastic leukemia","volume":"21","author":"Richmond","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/pbc.26064","article-title":"Initial testing (stage 1) of mk-8242-a novel mdm2 inhibitor-by the pediatric preclinical testing program","volume":"63","author":"Kang","year":"2016","journal-title":"Pediatric Blood Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the phase i trial of rg7112, a small-molecule mdm2 antagonist in leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.chembiol.2013.03.020","article-title":"Selective hdac1\/hdac2 inhibitors induce neuroblastoma differentiation","volume":"20","author":"Frumm","year":"2013","journal-title":"Chem. Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-410524-9.00001-3","article-title":"Mechanisms of epigenetic regulation of leukemia onset and progression","volume":"117","author":"Ntziachristos","year":"2013","journal-title":"Adv. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.2651","article-title":"Genetic inactivation of the polycomb repressive complex 2 in t cell acute lymphoblastic leukemia","volume":"18","author":"Ntziachristos","year":"2012","journal-title":"Nat. Med."},{"key":"ref_83","first-page":"961","article-title":"Chemotherapeutic studies of tumors, including leukemia, in children","volume":"79","author":"Farber","year":"1950","journal-title":"Am. J. Dis. Child."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood.V94.4.1209","article-title":"Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia","volume":"94","author":"Dordelmann","year":"1999","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11154-007-9059-8","article-title":"Glucocorticoid receptor physiology","volume":"8","author":"Heitzer","year":"2007","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.leukres.2009.08.007","article-title":"Polymorphisms in glucocorticoid receptor gene and the outcome of childhood acute lymphoblastic leukemia (all)","volume":"34","author":"Labuda","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/hon.2471","article-title":"Splicing variant profiles and single nucleotide polymorphisms of the glucocorticoid receptor gene in relation to glucocorticoid sensitivity of b-cell precursor acute lymphoblastic leukaemia","volume":"36","author":"Huang","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"235","DOI":"10.5045\/br.2015.50.4.235","article-title":"The prognostic value of glucocorticoid receptors for adult acute lymphoblastic leukemia","volume":"50","author":"Bedewy","year":"2015","journal-title":"Blood Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3109\/10428194.2014.951848","article-title":"Single nucleotide polymorphisms in non-coding region of the glucocorticoid receptor gene and prednisone response in childhood acute lymphoblastic leukemia","volume":"56","author":"Xue","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1158\/1078-0432.CCR-04-2097","article-title":"Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia","volume":"11","author":"Tissing","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nri2023","article-title":"Interleukin-7 receptor expression: Intelligent design","volume":"7","author":"Mazzucchelli","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3324\/haematol.2015.130179","article-title":"Targeted sequencing identifies associations between il7r-jak mutations and epigenetic modulators in t-cell acute lymphoblastic leukemia","volume":"100","author":"Vicente","year":"2015","journal-title":"Haematologica"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/leu.2016.83","article-title":"Mek and pi3k-akt inhibitors synergistically block activated il7 receptor signaling in t-cell acute lymphoblastic leukemia","volume":"30","author":"Uitdehaag","year":"2016","journal-title":"Leukemia"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/ng.924","article-title":"Oncogenic il7r gain-of-function mutations in childhood t-cell acute lymphoblastic leukemia","volume":"43","author":"Zenatti","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.278.5341.1309","article-title":"A tel-jak2 fusion protein with constitutive kinase activity in human leukemia","volume":"278","author":"Lacronique","year":"1997","journal-title":"Science"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1084\/jem.20122727","article-title":"Interleukin-7 receptor mutants initiate early t cell precursor leukemia in murine thymocyte progenitors with multipotent potential","volume":"211","author":"Treanor","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/leu.2016.100","article-title":"Loss-of-function mutations of dynamin 2 promote t-all by enhancing il-7 signalling","volume":"30","author":"Tremblay","year":"2016","journal-title":"Leukemia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/ng.587","article-title":"Deletion of the protein tyrosine phosphatase gene ptpn2 in t-cell acute lymphoblastic leukemia","volume":"42","author":"Kleppe","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s002770050495","article-title":"Effects of interleukin 3, interleukin 7, and b-cell growth factor on proliferation and drug resistance in vitro in childhood acute lymphoblastic leukemia","volume":"78","author":"Duyn","year":"1999","journal-title":"Ann. Hematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1182\/blood.V99.11.4109","article-title":"In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood t-cell acute lymphoblastic leukemia","volume":"99","author":"Wuchter","year":"2002","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1042\/BJ20112092","article-title":"Pi3k signalling in b- and t-lymphocytes: New developments and therapeutic advances","volume":"442","author":"So","year":"2012","journal-title":"Biochem. J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The pi3k pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Papa, A., and Pandolfi, P.P. (2019). The pten-pi3k axis in cancer. Biomolecules, 9.","DOI":"10.20944\/preprints201904.0127.v1"},{"key":"ref_104","first-page":"87","article-title":"The regulation of class ia pi 3-kinases by inter-subunit interactions","volume":"346","author":"Backer","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1038\/onc.2008.244","article-title":"Class i pi3k in oncogenic cellular transformation","volume":"27","author":"Zhao","year":"2008","journal-title":"Oncogene"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.4049\/jimmunol.175.5.2783","article-title":"Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase","volume":"175","author":"Webb","year":"2005","journal-title":"J. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1182\/blood-2009-02-206722","article-title":"High frequency of pten, pi3k, and akt abnormalities in t-cell acute lymphoblastic leukemia","volume":"114","author":"Gutierrez","year":"2009","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1636","article-title":"Mutational loss of pten induces resistance to notch1 inhibition in t-cell leukemia","volume":"13","author":"Palomero","year":"2007","journal-title":"Nat. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood-2014-03-562751","article-title":"Pten microdeletions in t-cell acute lymphoblastic leukemia are caused by illegitimate rag-mediated recombination events","volume":"124","author":"Mendes","year":"2014","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of nvp-bez235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Simioni, C., Martelli, A.M., Zauli, G., Melloni, E., and Neri, L.M. (2019). Targeting mtor in acute lymphoblastic leukemia. Cells, 8.","DOI":"10.3390\/cells8020190"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1182\/blood-2015-02-629485","article-title":"4ebp1\/c-myc\/puma and nf-kappab\/egr1\/bim pathways underlie cytotoxicity of mtor dual inhibitors in malignant lymphoid cells","volume":"127","author":"Yun","year":"2016","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the raf-mek-erk mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nri3445","article-title":"Regulation of innate and adaptive immunity by notch","volume":"13","author":"Radtke","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0952-7915(99)00067-9","article-title":"Notch signaling in t cell development","volume":"12","author":"Deftos","year":"2000","journal-title":"Curr. Opin. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fonc.2014.00170","article-title":"New approaches to target t-all","volume":"4","author":"Roti","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/ijc.31355","article-title":"Bepridil exhibits anti-leukemic activity associated with notch1 pathway inhibition in chronic lymphocytic leukemia","volume":"143","author":"Baldoni","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1615\/CritRevOncog.v16.i1-2.100","article-title":"Targeting notch1 in hematopoietic malignancy","volume":"16","author":"Roti","year":"2011","journal-title":"Crit. Rev. Oncog."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/bjc.2011.543","article-title":"Genetic and proteomic approaches to identify cancer drug targets","volume":"106","author":"Roti","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/sj.leu.2404409","article-title":"Activating mutations in notch1 in acute myeloid leukemia and lineage switch leukemias","volume":"20","author":"Palomero","year":"2006","journal-title":"Leukemia"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of notch1 in human t cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neulet.2019.02.011","article-title":"Gamma-secretase and its modulators: Twenty years and beyond","volume":"701","author":"Xia","year":"2019","journal-title":"Neurosci. Lett."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/toxsci\/kfh254","article-title":"Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation","volume":"82","author":"Milano","year":"2004","journal-title":"Toxicol. Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm.1900","article-title":"Gamma-secretase inhibitors reverse glucocorticoid resistance in t cell acute lymphoblastic leukemia","volume":"15","author":"Real","year":"2009","journal-title":"Nat. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/leu.2009.75","article-title":"Notch inhibition and glucocorticoid therapy in t-cell acute lymphoblastic leukemia","volume":"23","author":"Real","year":"2009","journal-title":"Leukemia"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"12044","DOI":"10.1016\/S0021-9258(18)37890-6","article-title":"Positive regulation of the glucocorticoid receptor in human t-cells sensitive to the cytolytic effects of glucocorticoids","volume":"263","author":"Eisen","year":"1988","journal-title":"J. Biol. Chem."},{"key":"ref_127","first-page":"1378","article-title":"Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic t cells","volume":"59","author":"Ramdas","year":"1999","journal-title":"Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1084\/jem.20070876","article-title":"Fbw7 mutations in leukemic cells mediate notch pathway activation and resistance to gamma-secretase inhibitors","volume":"204","author":"Grim","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1084\/jem.20070872","article-title":"The scffbw7 ubiquitin ligase complex as a tumor suppressor in t cell leukemia","volume":"204","author":"Thompson","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.febslet.2012.04.045","article-title":"The bromodomain interaction module","volume":"586","author":"Filippakopoulos","year":"2012","journal-title":"Febs Lett."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","article-title":"Histone recognition and large-scale structural analysis of the human bromodomain family","volume":"149","author":"Filippakopoulos","year":"2012","journal-title":"Cell"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/2040620715576662","article-title":"Inhibition of bromodomain and extra-terminal proteins (bet) as a potential therapeutic approach in haematological malignancies: Emerging preclinical and clinical evidence","volume":"6","author":"Chaidos","year":"2015","journal-title":"Ther. Adv. Hematol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/S0002-9440(10)63049-0","article-title":"BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19)","volume":"159","author":"French","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_134","first-page":"304","article-title":"BRD4-nut fusion oncogene: A novel mechanism in aggressive carcinoma","volume":"63","author":"French","year":"2003","journal-title":"Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of bet bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Loven","year":"2013","journal-title":"Cell"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"Bet bromodomain inhibition as a therapeutic strategy to target c-myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"Rnai screen identifies BRD4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.cell.2013.05.041","article-title":"The ubiquitin ligase fbxw7 modulates leukemia-initiating cell activity by regulating myc stability","volume":"153","author":"King","year":"2013","journal-title":"Cell"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ng.2913","article-title":"An epigenetic mechanism of resistance to targeted therapy in t cell acute lymphoblastic leukemia","volume":"46","author":"Knoechel","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ccell.2018.01.006","article-title":"Ezh2 and runx1 mutations collaborate to initiate lympho-myeloid leukemia in early thymic progenitors","volume":"33","author":"Booth","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1182\/blood.V84.12.4038.bloodjournal84124038","article-title":"Candidate tumor-suppressor genes mts1 (p16ink4a) and mts2 (p15ink4b) display frequent homozygous deletions in primary cells from t- but not from b-cell lineage acute lymphoblastic leukemias","volume":"84","author":"Hebert","year":"1994","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1078-0432.CCR-16-2825","article-title":"Beating the clock in t-cell acute lymphoblastic leukemia","volume":"23","author":"Carroll","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nrc3090","article-title":"Cyclin d as a therapeutic target in cancer","volume":"11","author":"Musgrove","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccr.2005.12.019","article-title":"Cyclin d1-dependent kinase activity in murine development and mammary tumorigenesis","volume":"9","author":"Landis","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/384470a0","article-title":"Cyclin d2 is an fsh-responsive gene involved in gonadal cell proliferation and oncogenesis","volume":"384","author":"Sicinski","year":"1996","journal-title":"Nature"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1535-6108(03)00301-5","article-title":"Requirement for cyclin d3 in lymphocyte development and t cell leukemias","volume":"4","author":"Sicinska","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/35082500","article-title":"Specific protection against breast cancers by cyclin d1 ablation","volume":"411","author":"Yu","year":"2001","journal-title":"Nature"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/sj.leu.2404008","article-title":"Cyclin d2 dysregulation by chromosomal translocations to tcr loci in t-cell acute lymphoblastic leukemias","volume":"20","author":"Clappier","year":"2006","journal-title":"Leukemia"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.4161\/cc.21127","article-title":"Cdk4\/6 inhibition antagonizes the cytotoxic response to anthracycline therapy","volume":"11","author":"McClendon","year":"2012","journal-title":"Cell Cycle"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"29075","DOI":"10.1074\/jbc.M112.365494","article-title":"Modification of the DNA damage response by therapeutic cdk4\/6 inhibition","volume":"287","author":"Dean","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","article-title":"The bcl-2 apoptotic switch in cancer development and therapy","volume":"26","author":"Adams","year":"2007","journal-title":"Oncogene"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"8590","DOI":"10.1038\/sj.onc.1207102","article-title":"The bcl-2 family: Roles in cell survival and oncogenesis","volume":"22","author":"Cory","year":"2003","journal-title":"Oncogene"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","article-title":"Bh3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions","volume":"332","author":"Letai","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.trecan.2016.07.001","article-title":"Targeting bcl-2-like proteins to kill cancer cells","volume":"2","author":"Cory","year":"2016","journal-title":"Trends Cancer"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1038\/onc.2009.52","article-title":"Mimicking the bh3 domain to kill cancer cells","volume":"27","author":"Letai","year":"2008","journal-title":"Oncogene"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: A non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase ii study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective bcl-2 inhibition by abt-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"Abt-199, a potent and selective bcl-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to bcl2 inhibition: Results of a phase i study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccr.2013.01.018","article-title":"Abt-199: Taking dead aim at bcl-2","volume":"23","author":"Davids","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: A multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/17474086.2018.1548931","article-title":"Venetoclax for the treatment of multiple myeloma","volume":"11","author":"Vaxman","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Tahir, S.K., Smith, M.L., Hessler, P., Rapp, L.R., Idler, K.B., Park, C.H., Leverson, J.D., and Lam, L.T. (2017). Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3383-5"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1080\/10428194.2017.1366999","article-title":"Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies","volume":"59","author":"Grant","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1038\/onc.2009.240","article-title":"Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent mcl-1 protein cleavage","volume":"28","author":"Yuan","year":"2009","journal-title":"Oncogene"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. Fda approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","article-title":"Selective inhibitors of nuclear export (sine)\u2014A novel class of anti-cancer agents","volume":"7","author":"Parikh","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.sbi.2010.09.008","article-title":"Recognition of nuclear targeting signals by karyopherin-beta proteins","volume":"20","author":"Xu","year":"2010","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ceb.2008.09.010","article-title":"Reorganization of the nuclear envelope during open mitosis","volume":"20","author":"Kutay","year":"2008","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/520609a","article-title":"Personalized medicine: Time for one-person trials","volume":"520","author":"Schork","year":"2015","journal-title":"Nature"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrc.2016.63","article-title":"The genetics and mechanisms of t cell acute lymphoblastic leukaemia","volume":"16","author":"Belver","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"Garnett","year":"2012","journal-title":"Nature"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia","volume":"3","author":"Pemovska","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","article-title":"Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia","volume":"129","author":"Frismantas","year":"2017","journal-title":"Blood"},{"key":"ref_180","first-page":"73","article-title":"Overcome resistance to chemotherapy by using drug sensitivity and resistance profiling in t-all","volume":"103","year":"2018","journal-title":"Haematologica"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/12\/3021\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:00:00Z","timestamp":1760187600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/12\/3021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":180,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["ijms20123021"],"URL":"https:\/\/doi.org\/10.3390\/ijms20123021","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]}}}